Azitra opens $3.5 million stock sale to fund operations
What's the deal? Azitra, a NYSE American-listed biotech, has entered a sales agreement with A.G.P./Alliance Global PartnersDealroom has a profile for this one. Try Dealroom → to sell up to $3.5 million of common stock through an at-the-market offering. The company disclosed the deal in a Form 8-K filing on September 28, 2026.
How it works? A.G.P. will act as sales agent, earning a 3% cash fee on gross proceeds. Shares can be sold on the NYSE American or other trading markets under Azitra's existing Form S-3 registration, which took effect on July 8, 2024.
Where does the money go? Net proceeds, if any, are earmarked for working capital and general corporate purposes. Azitra is under no obligation to sell shares and can suspend or end the offering at any time.
Why now? An at-the-market facility gives Azitra a flexible way to raise cash as needed rather than in a single fixed raise. Chief executive officer Francisco D. Salva signed the agreement on September 28, 2026.
When does it end? The offering concludes at the earliest of three points: all shares are sold, the registration statement expires three years after its effective date, or either party terminates the agreement.
The signal: ATM programs remain a common tool for small-cap listed companies that need steady access to capital without committing to a large discounted raise. For Azitra, the facility offers optional funding to keep operations running.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
